Covid-19 Vaccine Strategy Taskforce
M inutes – Wednesday 30 September
Mee
ting Details
Members in Attendance
MBIE: Peter Crabtree (chair), Prue
MFAT: David Taylor
Williams,
MOH: Maree Roberts; John Whaanga,
PHARMAC: Lisa Williams
Treasury: Melody Guy, Jess Hewat
DPMC: Sasha O’Dea, Philippa Yasbek
STAG: Ian Town, James Ussher (items 3-7)
Apologies
Chris James
Additional attendees
MBIE: Poppy Haynes, Karl Fergusson, Alastair Mackay, Stephanie Symynuk, Justine
Daw,
MFAT: Glenys Karran,
PHARMAC Andrew Oliver,
MOH Allison Bennett, Matt
Par, Kelvin Watson, Sue Gordon, Carl Billington,
Medsafe Derek Fitzgerald,
DPMC
Ben McBride
Action Points
2 Science Representation on the taskforce AGREED
No actions
3 Status report
No actions
4 Immunisation Strategy and Approach
Action:
1. Al ison to arrange regular updates at future Taskforce meetings
2. Ian to provide an update of the science view of Vaccine 1 end of November
5 Strategic Risks
Action:
3. Alastair to review risks for next meeting, specific reviews for
a. 08 Medsafe not approving , clarify issue is if Medsafe don’t approve when other
Like-minded countries have and also contractual implications
b. New Consider risk of Vaccine Hesitancy
c. 15 Precedent of 100% coverage, not seen as significant, drop
d. 17 NZ Isolationist stance, not seen as significant, drop
4. Philippa, and Simon to organise session to discuss interactions between vaccine rol out and
overal COVID-19 strategy.
6 Communications and Stakeholder engagement Plan APPROVED
Action
5. Karl to provide an update at future taskforce meetings
6. Karl to link in with the various Pacific Island networks
7 COVAX and International
Action
7. Glenys to work with Poppy and others on how the handover of COVAX purchasing from
MFAT to MBIE wil work, report back next taskforce meeting.
8 APA Update
Noted draft briefing on first APA, fol owing some polish this wil fol ow the normal signoff
approach
9 VAANZ update
Not covered in meeting, fol owed up by email round robin.